Refine Results
A Pan-Cancer View of the Immune Landscape in the Tumor Microenvironment...

Immune-based biomarkers for measurement of tumor microenviornment (TME)

Tumor Mutational Burden (TMB) analysis across multiple genomic platforms...

Why Tumor Mutational Burden (TMB)?

A Pan-cancer View of Immune Cell Activity, Immune Checkpoints and Tumor...

Aspects of immune cell activity and their pro and anti-tumor characteristics

Vaccine and Infectious Disease Testing Capabilities

End-to-end Laboratory Testing for Infectious Diseases and Vaccine Development

Immune Landscape Signatures from Gene Expression Analysis of Human Tumors

Signatures characterizing key immune cell subtypes, pathways, and individual genes

Significant Developments, Trends and Approaches in Next Generation Flow...

Q&A with Mark Edinger

A Next Generation Sequencing (NGS) Approach to Influenza Vaccine...

NGS influenza typing assay for vaccine and therapeutic development

Matched FFPE and ctDNA Analysis using Illumina TruSightTumor 170 NGS Assay

Technical feasibility for utilizing TruSightTumor 170 NGS assay (+UMIs) to analyze ctDNA

Validated bioanalytical methods list

LC/MS/MS Methods, Immunoassay Biomarker Methods and LC/MS Biomarker Methods

Bioinformatics and Computational Solutions for Genomic Insights

Next generation sequencing-based big data solutions

Clinical Trial Biospecimen and Consent Tracking

Clinical trials today involve sophisticated sample collection and analysis. Samples are tested to...

Using Labmatrix™ at a Big Biopharma Company to Reduce Clinical Trial...

The client’s primary objective was to establish a central environment for the life-cycle...